Revolution Medicines Reports 76.6% 12-Month Survival Rate for Rasonque
The latest data reveals a promising survival rate for Rasonque in treating metastatic pancreatic cancer.
Rasonque combined with GnP shows a 76.6% overall survival rate at 12 months.
The regimen achieved a 60.7% confirmed objective response rate.
FDA approved Rasonque for metastatic PDAC in August 2026.
Revolution Medicines, Inc. has announced significant findings from its ongoing Phase 1/2 clinical trial of Rasonque (daraxonrasib) in combination with gemcitabine and nab-paclitaxel (GnP) for patients with metastatic pancreatic adenocarcinoma (PDAC). As of September 28, 2026, data from 61 patients indicate a 12-month overall survival rate of 76.6%. These results will be presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
The trial, which focuses on patients with RAS-addicted cancers, reported a median follow-up of 18.3 months. The combination therapy demonstrated a confirmed objective response rate of 60.7%, with 8.2% of patients achieving complete responses. Additionally, the regimen maintained a high disease control rate of 90.2% and a median duration of response of 11.1 months, alongside a median progression-free survival of 12.8 months.
Safety data from the trial aligns with previous observations regarding Rasonque and GnP. The findings build on earlier results shared at the American Association for Cancer Research (AACR) Annual Meeting in April 2026. The FDA's approval of Rasonque for metastatic PDAC in August 2026 marked a significant milestone, allowing for accelerated access to this treatment under the agency's fast-track drug review program.
The implications of these results are substantial for patients suffering from metastatic pancreatic cancer, a condition known for its poor prognosis. With a promising survival rate and response metrics, Rasonque could become a vital option in the therapeutic landscape for this aggressive cancer type. The ongoing Phase 3 study, RASolve 308, will further evaluate zoldonrasib, another investigational therapy from Revolution Medicines, in treating metastatic lung cancer.
Looking ahead, Revolution Medicines is poised to continue its clinical trials and data presentations, with the potential for Rasonque to significantly impact treatment protocols for metastatic PDAC. Investors and stakeholders will be keenly observing the outcomes of ongoing studies and the company's strategic developments in the oncology sector.




